

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.1527

FR10239

ANTI-NXP2 ANTIBODIES: CLINICAL AND SEROLOGICAL ASSOCIATIONS IN A MULTICENTRIC ITALIAN STUDY

M. Fredi,1, A. Cavazzana1, A. Ceribelli1, M. G. Lazzaroni1, S. Barisotti2, M. Benuccci,1, L. Cavagna1, L. De Stefano1, A. Doria1,2, G. Emmi4, M. Fornaro4, F. Furini5, R. Gerli10, G. M. Giudizi2, M. Govoni3, A. Ghirardello6, Iaccarino6, F. Iannone8, M. Infantino4, A. Mathieu11, E. Marasco5, P. Migliorini12, B. Palterer7, F. Parronchi7, M. Piga11, F. Pratesi12, A. Radice13, C. Selmi2, V. Ricciieri14, M. Tamposi15, G. Zanfruneto, A. Tincani1, F. Franceschini1. 1Rheumatology Unit Spedali Civili Università di Brescia, Brescia, Italy; 2Rheumatology Unit Università Humanitas, Rozzano, Italy; 3Rheumatology Unit AOU Pisana, Pisa, Italy; 4Rheumatology Unit Ospedale S. Giovanni di Dio, Firenze, Italy; 5Rheumatology Unit Policlinico San Matteo, Pavia, Italy; 6Rheumatology Unit Università Studi di Padova, Padova, Italy; 7Rheumatology Unit Università di Bari, Bari, Italy; 8Rheumatology Unit Università di Ferrara, Ferrara, Italy; 9Rheumatology Unit Università di Perugia, Perugia, Italy; 10Rheumatology Unit, Università di Cagliari, Cagliari, Italy; 11Immunologia, AO Università Pisana, Pisa, Italy; 12Microbiologia e Virologia Ospedale San Carlo Borromeo, Milano, Italy; 13Policlinico Umberto I, Roma, Italy; 14Laboratorio Patologia Clinica Policlinico Bari, Bari, Italy

Background: Anti-NXP2 antibodies is considered a serological marker of dermatomyositis (DM), with calcinosis, severe myositis and, in some series, cancer. Historically, these associations have been detected with immunoprecipitation (IP), but in the last few years commercial line blot (LB) assay have been released. Objectives: to analyze the clinical features associated to anti-NXP2 antibodies, including the onset of concomitant cancers, both with LB and homemade IP

Methods: clinical and serological data from medical charts of 213 patients with a diagnosis of inflammatory myositis without anti-NXP2 (NXP2-), followed-up by two third-level Centers, and 61 anti-NXP2+ patients from 10 Rheumatological centers were analyzed. Anti-myositis specific (MSA) and anti-myositis associated antibodies (MAA) were detected in single centers by LB (Euroimmun Autoimmune Inflammatory Myopathies 16 antigens). Anti-NXP2 was confirmed by protein and RNA IP, as previously described (1)

Results: clinical diagnosis of anti-NXP2+ positive with LB were 42 DM, 11 PM, 100%. Inclusion of concomitant cancers, both with LB and homemade IP